Combination of sunitinib and (177)Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies with targeted radioimmunotherapy (RIT). We studied tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosterwijk-Wakka, Jeannette C., de Weijert, Mirjam C.A., Franssen, Gerben M., Kolev, Dimitar R., de Haan, Ton A.F.J., Boerman, Otto C., Mulders, Peter F.A., Oosterwijk, Egbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309230/
https://www.ncbi.nlm.nih.gov/pubmed/35878454
http://dx.doi.org/10.1016/j.neo.2022.100826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309230/
https://www.ncbi.nlm.nih.gov/pubmed/35878454
http://dx.doi.org/10.1016/j.neo.2022.100826

Ejemplares similares